Testing three treatments together for glioblastoma that has come back
Original title: OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage test in people, not care your own doctor can give you.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests whether three treatments can be given together safely.
Who this trial is for. This trial is for adults with glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary that has come back or is growing. It tests three treatments given together: tumor treating fields: A treatment that uses alternating electric fields to interfere with tumor cells dividing. It is given through pads worn on the scalp, connected to a portable device. The device is often called Optune. See the glossary GIO, MRI guided laser surgery, and pembrolizumab.
Where it stands. This trial has not reported results. It is looking at whether the three treatments are safe. It is also looking at whether they can be given together. The answer is not in yet.
What this means, and what it doesn't
What it could mean: Someone in this situation could ask their care team about this trial. The care team can say if it makes sense to look into.
What it doesn't mean: This does not mean the three treatments work. A trial is a test, not proven care. Being in one is not a promise that it will help. It is not a cure.
Source: ClinicalTrials.gov, September 23, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.